TRH and urogenital neoplasm: Antibiotic rifaximin (RF) modulates prostatic TRH and TRH-like peptide levels—with the largest peripheral tissue changes in the prostate—via gut microbiome alteration, indicating the gut microbiome-TRH signaling pathway as a potential intervention target for prostatitis (26).